|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeting Rho and Rho-kinase inthe treatment of cardiovascular disease 显示文摘 | Budzyn K Marley P D Sobey C G | 2006 | Trends in pharmacologicalsciences2006，27，2： | 1 |
| 2 | Spectroscopic evidence for organic diacid complexation with silica in aqueous systems-I oxalic acid 显示文摘 | Marley N A Bennet P Janecky D R | 1989 | Organic Geochemistry1989，14，3： | 1 |
| 3 | Distribution of transferring synthesis in brain and other tissues in the rat显示文摘 | Aldred A R Dickson P W Marley P D | 1987 | J Biol Chem1987，262，： | 1 |
| 4 | The attenuation of ultraviolet radiation in high dissolved organic carbon waters of wetlands and lakes on northern Great Plains显示文摘 | Michael T A Richard D R Kasai F Marley J W Vijay P T Amanda J P Hakumat R Hendrika J D L | 2000 | Limnol Oceanogr2000，45，： | 1 |
| 5 | Chromogranin A:secretion of processed products from the stimulated retrogradely perfused bovine adrenal gland显示文摘 | Helle K B Marley P D Angeletti R H | 1993 | Neuroendocrinology1993，5，4： | 1 |
| 6 | Different contributions of voltage-sensitive Ca^2+ channels to istamine-induced catecholamine release and tyrosine hydroxylase activation in bovine adrenal chromaffin cells显示文摘 | O'Farrell M Marley P D | 1999 | Cell Calcium1999，25，： | 1 |
| 7 | Triggers and barriers to financial inclusion:The use of ICT-based branchless banking in an Amazon county显示文摘 | EDUARDO D RENE B MARLEI P | 2012 | Electronic Commerce Research and Applications2012，11，5： | 1 |
| 8 | Mexico City aerosol analysis during MILAGRO using high resolution aerosol mass spectrometry at the urban supersite (T0)-Part 1:Fine particle composition and organic source apportionment显示文摘 | Aiken A C Salcedo D Cubison M J Huffman J A DeCarlo P F Ulbrich I M Docherty K S Sueper D Kimmel J R Worsnop D R Trimborn A Northway M Stone E A Schauer J J Volkamer R M Fortner E de Foy B Wang J Laskin A Shutthanandan V Zheng J Zhang R Gaffney J Marley N | | 0，，17： | 1 |
| 9 | Mechanisms in histamine-mediated secretion from adrenal chromaffin cells显示文摘 | MARLEY P D | 2003 | Pharmacol ther2003，98，： | 1 |
| 10 | 显示文摘 | BUDZYN K MARLEY P D SOBEY C G | 2006 | Trends Pharmaeol Sci2006，27，2： | 1 |
| 11 | Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil显示文摘BACKGROUND Crohn’s disease(CD)and ulcerative colitis(UC)are inflammatory bowel diseases(IBDs)with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden,especially in patients with moderate-to-severe disease.The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil(RISE BR)study was a noninterventional study designed to evaluate disease control,treatment patterns,disease burden and health-related quality of life in patients with moderate-to-severe active IBD.We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.AIM To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil.METHODS This was a prospective,noninterventional study of adult patients with active Crohn’s disease(CD:Harvey-Bradshaw Index≥8,CD Activity Index≥220),inadequate CD control(i.e.,calprotectin>200μg/g or colonoscopy previous results),or active ulcerative colitis(UC:Partial Mayo score≥5).Enrollment occurred in 14 centers from October 2016 to February 2017.The proportion of active IBD patients after 9-12 mo of follow-up,Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation,discontinuation and dose changes were examined.RESULTS The study included 118 CD and 36 UC patients,with mean±SD ages of 43.3±12.6 and 44.9±16.5 years,respectively.The most frequent drug classes at index were biologics for CD(62.7%)and 5-aminosalicylate derivates for UC patients(91.7%).During follow-up,65.3%of CD and 86.1%of UC patients initiated a new treatment at least once.Discontinuations/dose changes occurred in 68.1%of CD patients[median 2.0(IQR:2-5)]and 94.3%of UC patients[median 4.0(IQR:3-7)].On average,CD and UC patients had 4.4±2.6 and 5.0±3.3 outpatient visits,respectively.The median time to first mild or no activity was 319(IQR:239-358)d for CD and 320(IQR:288-358)d for UC patients.At 9-12 mo,22.0%of CD and 20.0%of UC patients had active disease.CONCLUSION Although a marked proportion of active IBD patients achieved disease control within one year,the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting. | Ligia Yukie Sassaki Sender J Miszputen Roberto Luiz Kaiser Junior Wilson R Catapani Mauro Bafutto António S Scotton Cyrla Zaltman Julio Pinheiro Baima Hagata S Ramos Mikaell Alexandre Gouvea Faria Carolina D Gonçalves Isabella Miranda Guimaraes Cristina Flores Heda M B S Amarante Rodrigo Bremer Nones JoséMiguel Luz Parente Murilo Moura Lima Júlio Maria Chebli Maria de Lourdes Abreu Ferrari Julia F Campos Maria G P Sanna Odery Ramos Rogério Serafim Parra Jose J R da Rocha Omar Feres Marley R Feitosa Rosana Fusaro Caratin Juliana Tosta Senra Genoile Oliveira Santana | 2021 | World Journal of Gastroenterology2021，27，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员